A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)

Registry ID

MK-2870-022

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2026-03-23

Last update

2025-06-26

Conditions

• OVARIAN CANCER
• PLATINUM-RESISTANT OVARIAN CANCER

Related clinical trials

• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE IN PARTICIPANTS WITH NEWLY DIAGNOSE ADVANCED HRD-NEGATIVE OVARIAN CANCER FOLLOWING FIRST-LINE PLATINUMBASED CHEMOTHERAPY (TROFUSE-021/ENGOTOV85/GOG-3102)
• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
• MULTI-ARM PHASE 2 STUDY OF UBAMATAMAB (REGN4018; MUC16×CD3 BISPECIFIC ANTIBODY) WITH OR WITHOUT ADDITIONAL AGENTS IN PLATINUM-RESISTANT OVARIAN CANCER
• CATALINA-2: A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF TORL-1-23 IN WOMEN WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCERS) EXPRESSING CLAUDIN 6 (CLDN6)
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF RINATABART SESUTECAN (RINA-S) VERSUS TREATMENT OF INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
• A RANDOMIZED PHASE 2 STUDY OF OCULAR TOXICITY EVALUATION AND MITIGATION DURING TREATMENT WITH MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH RECURRENT OVARIAN CANCER WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION

View on source registry